Webinar: Adverse Drug Interaction Risks in Genetically Defined Subpopulations



March 15, 2017

Presenter: Maciej Czerwinski, Ph.D., Director of Sekisui XenoTech Products R&D Aired: June 20, 2016 Synopsis: An increased appreciation of the effects of genetic variability on the pharmacokinetic and pharmacodynamic properties of xenobiotics creates a need for specialized tools to evaluate new drugs from the pharmacogenomics perspective. Preclinical examination of drug metabolism with consideration of patient population diversity may reduce the risk of adverse effects upon first administration of a xenobiotic to humans and during further phases of drug testing and expansive use. An extensive polymorphism of drug metabolizing enzymes and drug transporters is well established. Human genetically-defined liver microsomes and most recently pooled cryopreserved hepatocytes constitute test systems for the pharmacogenetically-informed study of drug metabolism. Characterization of Sekisui XenoTech Geneknown™ hepatocytes and criteria applied for creating genetically-defined pools of cells will be presented as part of the discussion. Key concepts discussed in this webinar include: - Effects of drug metabolizing enzyme polymorphisms on drug disposition - Safety concerns associated with developing one dose for diverse patient population - Genetic basis for some of the polymorphisms of important drug metabolizing enzymes - Selecting the best test system to study the effects of specific genetic variants on drug metabolism - Donor selection for effective test pools Download Slides: https://www.xenotech.com/webinar-slides/june_genetic_di_risks_webinar_slides Questions: https://www.xenotech.com/contact-us Upcoming Webinars: https://www.xenotech.com/scientific-resources/upcoming-webinars Other Previously Aired Webinars: https://www.xenotech.com/scientific-resources/webinar-series

Analytical TechniquesBiopharmaCell CultureDrug Discovery

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.